Antibiotic resistance is one of the major health threats facing global as well as domestic populations, however it is not well characterized in pediatric patients. Pediatric patients receiving cancer-directed therapy have several risk factors implicated in development of antibiotic resistance including multiple courses of antibiotics, repeated exposures to the hospital environment, indwelling devices and chemotherapy-related damage to mucosal barriers. The investigators propose to capitalize upon the unique position of St. Jude Global within the global pediatric oncology community by using its regional alliance network to describe the molecular epidemiology of antibiotic resistance in Gram-negative bacteria in this population. Primary Objectives 1. Describe the epidemiology and the phenotypic and previously determined molecular determinants of antimicrobial resistance in Gram-negative organisms isolated from pediatric diagnostic specimens in selected Central American and US sites with capacity to treat pediatric cancer 2. Utilize strain typing by whole genome sequencing to describe relatedness between organisms at participating sites
Participating clinical microbiology laboratories will flag any Gram-negative bacteria meeting inclusion criteria. Bacteria will be subcultured; one sample will be lysed and shipped to St. Jude; the remaining sample will be stored onsite for the duration of the study. Samples of bacteria from both oncology and non-oncology patients will be included. Whole genome sequencing will be performed on the bacterial samples at St. Jude and the genotypic and phenotypic antimicrobial resistance testing (AST) results compared. Genotypic results will additionally be used to describe phylogenetic relationships and potential transmission events both within and between sites. Each participating location will collect limited clinical data corresponding to disease and treatment related factors on the affected patient. This will include sociodemographic variables, oncologic diagnosis, treatment phase, presence of a central venous catheter or other foreign body, antibiotic treatment within the past month, and previous history of colonization or infection by a resistant organism.
Study Type
OBSERVATIONAL
Enrollment
560
St. Jude Children's Research Hospital
Memphis, Tennessee, United States
Texas Children's Hospital
Houston, Texas, United States
Hospital Nacional de Niños Benjamín Bloom
San Salvador, El Salvador
Unidad Nacional de Oncología Pediátrica
Guatemala City, Guatemala
Hospital del Niño
Panama City, Panama
Patterns of organism and resistance in participating sites
Number of isolated organisms by anatomic site and geographic site
Time frame: approximately 6 months after completion of data collection
Patterns of organism and resistance in participating sites
Number of antibiotic resistance genes/mutations of interest by geographic site
Time frame: approximately 6 months after completion of data collection
Patterns of organism and resistance in participating sites
Correlation of known mutations/genes of interest with drug resistance phenotype
Time frame: approximately 6 months after completion of data collection
Genetic relatedness between bacteria at participating sites
Whole genome sequencing results will be used to describe whether isolated organisms appear to be related phylogenetically.
Time frame: approximately 6 months after completion of data collection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.